Status:
COMPLETED
Tranexamic Acid for Total Knee Arthroscopy
Lead Sponsor:
The Miriam Hospital
Conditions:
Blood Loss, Surgical
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this investigation is to determine the most effective regimen of administration of tranexamic acid to improve clinical outcome among patients undergoing total knee arthroplasty.
Detailed Description
Tranexamic acid (TXA) is synthetic lysine analog, which acts as anti-fibrinolytic agent by preventing conversion of plasminogen in to plasmin. Various regimens of TXA administration (routes, doses, ti...
Eligibility Criteria
Inclusion
- \- Adult patients who are scheduled to undergo total knee arthroplasty will be approached to participate.
Exclusion
- Known allergy to TXA
- History of venous or arterial thrombosis within 12 months
- History of thromboembolic event within 12 months
- Acute ischemic event (stroke, transient ischemic attack, myocardial infarction, ischemic retinopathy) within 6 months
- Known congenital thrombophilia
- Relative Contraindications:
- History of seizures
- Impaired kidney function (Glomerular filtration rate \< 30 ml/min)
Key Trial Info
Start Date :
October 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 8 2021
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT04443920
Start Date
October 29 2019
End Date
January 8 2021
Last Update
June 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Miriam Hospital
Providence, Rhode Island, United States, 02903